Drugs Made In America Acquisition II Corp. Files 2025 10-K
Ticker: DMII · Form: 10-K · Filed: Apr 15, 2026
Sentiment: neutral
Topics: 10-K, annual-report, financials
TL;DR
DMAA files 2025 10-K. Full financials & policies out.
AI Summary
Drugs Made In America Acquisition II Corp. filed its annual report on Form 10-K on April 15, 2026, for the fiscal year ending December 31, 2025. The filing includes the company's audited financial statements, a description of its securities, and corporate policies such as an insider trading policy and a clawback policy. The company's mailing and business address is 420 Lexington Avenue, Suite 1402, New York, NY 10170.
Why It Matters
This 10-K filing provides a comprehensive overview of Drugs Made In America Acquisition II Corp.'s financial health and corporate governance for the 2025 fiscal year, crucial for investors and stakeholders.
Risk Assessment
Risk Level: low — This filing is a standard annual report and does not contain immediate news of significant financial distress or major operational changes.
Key Numbers
- 10-K — Form Type (Annual report filed by the company)
- 2025-12-31 — Fiscal Year End (The end date of the reporting period)
Key Players & Entities
- Drugs Made In America Acquisition II Corp. (company) — Filer of the 10-K report
- 0002040475 (company) — CIK number for Drugs Made In America Acquisition II Corp.
- 2026-04-15 (date) — Filing date of the 10-K
- 2025-12-31 (date) — Period of report for the 10-K
- 420 Lexington Avenue Suite 1402 New York NY 10170 (address) — Mailing and business address of the company
FAQ
What is the primary purpose of the filed document?
The primary purpose of the filed document is to serve as an annual report (Form 10-K) for Drugs Made In America Acquisition II Corp., detailing its financial performance and corporate information for the fiscal year ending December 31, 2025.
When was this 10-K filing accepted by the SEC?
This 10-K filing was accepted by the SEC on April 15, 2026.
What is the CIK number associated with Drugs Made In America Acquisition II Corp.?
The CIK number associated with Drugs Made In America Acquisition II Corp. is 0002040475.
Where is the company's principal place of business located?
The company's principal place of business is located at 420 Lexington Avenue, Suite 1402, New York, NY 10170.
What types of exhibits are included with this 10-K filing?
Exhibits include the annual report itself (ea0285468-10k_drugs2.htm), description of securities, insider trading policy, certifications, and a clawback policy.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on April 15, 2026 regarding Drugs Made In America Acquisition II Corp. (DMII).